FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3150502808> ?p ?o ?g. }

• W3150502808 endingPage "1670" @default.
• W3150502808 startingPage "1663" @default.
• W3150502808 abstract "IFN-related pathways have not been studied in morphea, and biomarkers are needed. We sought to characterize morphea serum cytokine imbalance and IFN-related gene expression in blood and skin to address this gap by performing a case-control study of 87 participants with morphea and 26 healthy control subjects. We used multiplexed immunoassays to determine serum cytokine concentrations, performed transcriptional profiling of whole blood and lesional morphea skin, and used double-staining immunohistochemistry to determine the cutaneous cellular source of CXCL9. We found that CXCL9 was present at increased concentrations in morphea serum (P < 0.0001), as were other T helper type 1 cytokines. CXCL9 serum concentration correlated with the modified Localized Scleroderma Skin Severity Index (r = 0.44, P = 0.0001), a validated measure of disease activity. CXCL9 gene expression was also increased in inflammatory lesional morphea skin (fold change = 30.6, P = 0.006), and preliminary transcriptional profiling showed little evidence for IFN signature in whole blood. Double-staining immunohistochemistry showed CXCL9 co-localized with CD68+ dermal macrophages. In summary, inflammatory morphea is characterized by T helper type 1 cytokine imbalance in serum, particularly CXCL9, which is associated with disease activity. CXCL9 expression in lesional macrophages implicates the skin as the source of circulating cytokines. CXCL9 is a promising biomarker of disease activity in morphea. IFN-related pathways have not been studied in morphea, and biomarkers are needed. We sought to characterize morphea serum cytokine imbalance and IFN-related gene expression in blood and skin to address this gap by performing a case-control study of 87 participants with morphea and 26 healthy control subjects. We used multiplexed immunoassays to determine serum cytokine concentrations, performed transcriptional profiling of whole blood and lesional morphea skin, and used double-staining immunohistochemistry to determine the cutaneous cellular source of CXCL9. We found that CXCL9 was present at increased concentrations in morphea serum (P < 0.0001), as were other T helper type 1 cytokines. CXCL9 serum concentration correlated with the modified Localized Scleroderma Skin Severity Index (r = 0.44, P = 0.0001), a validated measure of disease activity. CXCL9 gene expression was also increased in inflammatory lesional morphea skin (fold change = 30.6, P = 0.006), and preliminary transcriptional profiling showed little evidence for IFN signature in whole blood. Double-staining immunohistochemistry showed CXCL9 co-localized with CD68+ dermal macrophages. In summary, inflammatory morphea is characterized by T helper type 1 cytokine imbalance in serum, particularly CXCL9, which is associated with disease activity. CXCL9 expression in lesional macrophages implicates the skin as the source of circulating cytokines. CXCL9 is a promising biomarker of disease activity in morphea." @default.
• W3150502808 created "2021-04-13" @default.
• W3150502808 creator A5010863112 @default.
• W3150502808 creator A5016380746 @default.
• W3150502808 creator A5033110195 @default.
• W3150502808 creator A5047313225 @default.
• W3150502808 creator A5049988509 @default.
• W3150502808 creator A5057077181 @default.
• W3150502808 creator A5059782253 @default.
• W3150502808 creator A5065078379 @default.
• W3150502808 date "2017-08-01" @default.
• W3150502808 modified "2023-10-12" @default.
• W3150502808 title "Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea" @default.
• W3150502808 cites W1463896243 @default.
• W3150502808 cites W1540350711 @default.
• W3150502808 cites W1964695094 @default.
• W3150502808 cites W1966097188 @default.
• W3150502808 cites W1970408063 @default.
• W3150502808 cites W1971294942 @default.
• W3150502808 cites W1975352805 @default.
• W3150502808 cites W1999530398 @default.
• W3150502808 cites W2006399653 @default.
• W3150502808 cites W2008423777 @default.
• W3150502808 cites W2017990928 @default.
• W3150502808 cites W2040477022 @default.
• W3150502808 cites W2049244261 @default.
• W3150502808 cites W2051734282 @default.
• W3150502808 cites W2070980944 @default.
• W3150502808 cites W2078981467 @default.
• W3150502808 cites W2094596462 @default.
• W3150502808 cites W2107452215 @default.
• W3150502808 cites W2111871990 @default.
• W3150502808 cites W2112763983 @default.
• W3150502808 cites W2130858592 @default.
• W3150502808 cites W2141014999 @default.
• W3150502808 cites W2144251393 @default.
• W3150502808 cites W2158781546 @default.
• W3150502808 cites W2163091927 @default.
• W3150502808 cites W2164368832 @default.
• W3150502808 cites W2165516192 @default.
• W3150502808 cites W2315987995 @default.
• W3150502808 cites W4239432044 @default.
• W3150502808 doi "https://doi.org/10.1016/j.jid.2017.04.008" @default.
• W3150502808 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6217816" @default.
• W3150502808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28450066" @default.
• W3150502808 hasPublicationYear "2017" @default.
• W3150502808 type Work @default.
• W3150502808 sameAs 3150502808 @default.
• W3150502808 citedByCount "40" @default.
• W3150502808 countsByYear W31505028082017 @default.
• W3150502808 countsByYear W31505028082018 @default.
• W3150502808 countsByYear W31505028082019 @default.
• W3150502808 countsByYear W31505028082020 @default.
• W3150502808 countsByYear W31505028082021 @default.
• W3150502808 countsByYear W31505028082022 @default.
• W3150502808 countsByYear W31505028082023 @default.
• W3150502808 crossrefType "journal-article" @default.
• W3150502808 hasAuthorship W3150502808A5010863112 @default.
• W3150502808 hasAuthorship W3150502808A5016380746 @default.
• W3150502808 hasAuthorship W3150502808A5033110195 @default.
• W3150502808 hasAuthorship W3150502808A5047313225 @default.
• W3150502808 hasAuthorship W3150502808A5049988509 @default.
• W3150502808 hasAuthorship W3150502808A5057077181 @default.
• W3150502808 hasAuthorship W3150502808A5059782253 @default.
• W3150502808 hasAuthorship W3150502808A5065078379 @default.
• W3150502808 hasBestOaLocation W31505028081 @default.
• W3150502808 hasConcept C13373296 @default.
• W3150502808 hasConcept C142724271 @default.
• W3150502808 hasConcept C17502307 @default.
• W3150502808 hasConcept C203014093 @default.
• W3150502808 hasConcept C2775934546 @default.
• W3150502808 hasConcept C2775938904 @default.
• W3150502808 hasConcept C2776914184 @default.
• W3150502808 hasConcept C2778690821 @default.
• W3150502808 hasConcept C2781197716 @default.
• W3150502808 hasConcept C55493867 @default.
• W3150502808 hasConcept C5858377 @default.
• W3150502808 hasConcept C71924100 @default.
• W3150502808 hasConcept C86803240 @default.
• W3150502808 hasConceptScore W3150502808C13373296 @default.
• W3150502808 hasConceptScore W3150502808C142724271 @default.
• W3150502808 hasConceptScore W3150502808C17502307 @default.
• W3150502808 hasConceptScore W3150502808C203014093 @default.
• W3150502808 hasConceptScore W3150502808C2775934546 @default.
• W3150502808 hasConceptScore W3150502808C2775938904 @default.
• W3150502808 hasConceptScore W3150502808C2776914184 @default.
• W3150502808 hasConceptScore W3150502808C2778690821 @default.
• W3150502808 hasConceptScore W3150502808C2781197716 @default.
• W3150502808 hasConceptScore W3150502808C55493867 @default.
• W3150502808 hasConceptScore W3150502808C5858377 @default.
• W3150502808 hasConceptScore W3150502808C71924100 @default.
• W3150502808 hasConceptScore W3150502808C86803240 @default.
• W3150502808 hasIssue "8" @default.
• W3150502808 hasLocation W31505028081 @default.
• W3150502808 hasLocation W31505028082 @default.
• W3150502808 hasLocation W31505028083 @default.
• W3150502808 hasLocation W31505028084 @default.
• W3150502808 hasOpenAccess W3150502808 @default.

• next